IR-MED Inc. specializes in developing non-invasive, AI-driven spectrographic analysis technology designed to assist healthcare professionals in real-time assessment of blood and tissue at the point of care. Their flagship product, PressureSafe™, is a handheld device aimed at revolutionizing the early detection of pressure injuries (PIs), which are a significant healthcare challenge, costing the U.S. healthcare system $26.8 billion annually and resulting in 60,000 deaths each year. Key Features and Functionality: - Infrared Spectroscopy: Utilizes harmless infrared reflectance spectroscopy to gather bio-information from a patient's blood and tissue non-invasively. - AI-Powered Decision Support: Employs AI algorithms to analyze the collected data, providing real-time clinical decision support to healthcare providers. - Skin Tone Agnostic: Effectively detects early-stage pressure injuries across all skin tones by analyzing biomarkers beneath the skin's surface, addressing healthcare disparities. - High Accuracy: Demonstrated over 90% accuracy in detecting pressure injuries based on interim results from multicenter studies. Primary Value and User Benefits: PressureSafe™ addresses the critical need for early detection of pressure injuries, which are often preventable yet prevalent, affecting 2.5 million people annually in the U.S. By providing a non-invasive, accurate, and skin tone agnostic solution, PressureSafe™ empowers healthcare professionals to identify and treat pressure injuries at an early stage, potentially reducing patient suffering, preventing complications, and decreasing associated healthcare costs. This innovation promotes equitable healthcare by ensuring effective assessment for individuals of all skin tones.